Avidity Biosciences Executive Compensation (FY24)
RNAM · Executive and director compensation, fiscal 2022 to 2024
Chief executive, fiscal 2024 ◇ Sarah Boyce | Chief executive pay ratio ◇ To the median employee |
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
The Avidity Biosciences brief, $500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Data as of November 3, 2026Latest filing (DEF 14A): April 29, 2025
1 filing cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
234 figures on this page, cited to the filing that reported them. See the citations
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Sarah Boyce: $11,139,719 → $14,176,480 (27.3% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Avidity Biosciences' chief executive and what were they paid?
Total compensation for Sarah Boyce, President and Chief Executive Officer, came to $14,176,480 in fiscal 2024. Boyce's total moved 27.3% higher from the $11,139,719 reported for fiscal 2023.
Which companies are in Avidity Biosciences' peer group?
The disclosed peer group names Arcturus Therapeutics Holdings, Beam Therapeutics, Crinetics Pharmaceuticals, Dyne Therapeutics and Erasca, among others.
What is Avidity Biosciences' chief executive pay ratio?
For fiscal 2024, the company reported a chief executive pay ratio of 48:1, against median employee compensation of $297,345.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Sarah Boyce President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Teresa McCarthy Chief Human Resources Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
W. Michael Flanagan Chief Scientific Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Michael MacLean Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Sarah Boyce President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
W. Michael Flanagan Chief Scientific Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Michael MacLean Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Teresa McCarthy Chief Human Resources Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Sarah Boyce President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
John Moriarty Chief Legal Officer and Corporate Secretary | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Michael MacLean Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
W. Michael Flanagan Chief Scientific Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Teresa McCarthy Chief Human Resources Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| John B. Moriarty Jr | PSU | ◇ | — | ◇ | — | — | — | ◇ |
| John B. Moriarty Jr | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| John B. Moriarty Jr | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Michael F. MacLean | PSU | ◇ | — | ◇ | — | — | — | ◇ |
| Michael F. MacLean | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Michael F. MacLean | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Sarah Boyce | PSU | ◇ | — | ◇ | — | — | — | ◇ |
| Sarah Boyce | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Sarah Boyce | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Teresa McCarthy | PSU | ◇ | — | ◇ | — | — | — | ◇ |
| Teresa McCarthy | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Teresa McCarthy | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| W. Michael Flanagan | PSU | ◇ | — | ◇ | — | — | — | ◇ |
| W. Michael Flanagan | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| W. Michael Flanagan | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Sarah Boyce | PSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | January 20, 2034 | |
| Option | ◇ | — | ◇ | January 20, 2033 | |
| Option | ◇ | — | ◇ | September 11, 2033 | |
| Option | ◇ | — | ◇ | January 21, 2032 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | February 2, 2031 | |
| John Moriarty | Option | ◇ | — | ◇ | August 1, 2034 |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Michael MacLean | Option | ◇ | — | ◇ | January 20, 2034 |
| Option | ◇ | — | ◇ | January 20, 2033 | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | September 11, 2033 | |
| Option | ◇ | — | ◇ | January 21, 2032 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | February 2, 2031 | |
| W. Flanagan | Option | ◇ | — | ◇ | January 20, 2033 |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | January 20, 2034 | |
| Option | ◇ | — | ◇ | September 11, 2033 | |
| Option | ◇ | — | ◇ | January 21, 2032 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | January 21, 2031 | |
| Teresa McCarthy | PSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | January 20, 2034 | |
| Option | ◇ | — | ◇ | January 20, 2033 | |
| Option | ◇ | — | ◇ | January 21, 2032 | |
| Option | ◇ | — | ◇ | September 11, 2033 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | February 2, 2031 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2024
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Simona Skerjanec | ◇ | — | ◇ | — | — | — | ◇ |
Troy Wilson, Ph.D., J.D Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Noreen Henig, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Carsten Boess | ◇ | — | ◇ | — | — | — | ◇ |
Edward M. Kaye, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Tamar Thompson | ◇ | — | ◇ | — | — | — | ◇ |
Jean Kim | ◇ | — | ◇ | — | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
- Arcturus Therapeutics Holdings ARCT
- Beam Therapeutics BEAM
- Crinetics Pharmaceuticals CRNX
- Dyne Therapeutics DYN
- Erasca ERAS
- IGM Biosciences IGM
- Inhibrx Inc INBX
- Janux Therapeutics JANX
- Kymera Therapeutics KYMR
- Pliant Therapeutics PLRX
- RAPT Therapeutics RAPT
- Rocket Pharmaceuticals RCKT
- Stoke Therapeutics STOK
- Vaxcyte PCVX
- Ventyx Biosciences VTYX
- Verve Therapeutics VERV
- Zentalis Pharmaceuticals ZNTL
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Sarah Boyce (President and Chief Executive Officer), FY2024 total compensation $14,176,480 (base salary $659,900) [exec_comp, SEC accession 0001599901-25-000092, filed 2025-04-29]What this page does not include
Everything above is a fact Avidity Biosciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Avidity Biosciences sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
234 figures on this page, cited to the filing that reported them.
234 cited to the filing
Documents cited
- 0001599901-25-000092CEO PAY RATIO · COMPENSATION TABLES · DIRECTOR COMPENSATION
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Avidity Biosciences executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/RNAM (accessed 2026).
Short form: data: Velarion
The Avidity Biosciences brief, $500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
1 filing cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Avidity Biosciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Avidity Biosciences discloses
The companies named in RNAM's own disclosed peer group.
Arcturus Therapeutics HoldingsBeam TherapeuticsCrinetics PharmaceuticalsDyne TherapeuticsErascaIGM BiosciencesInhibrx IncJanux TherapeuticsKymera TherapeuticsPliant TherapeuticsRAPT TherapeuticsRocket PharmaceuticalsStoke TherapeuticsVaxcyteVentyx BiosciencesVerve TherapeuticsZentalis Pharmaceuticals
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}